Tufts Medical Center - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first unrelated transplants performed between January 2007 and December 2009. It only includes patients with known survival status at one year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year - they have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.

Diagnosis	0-9 Yrs	10-19 Yrs	20-29 Yrs	30-39 Yrs	40-49 Yrs	50-59 Yrs	60+ Yrs	Overall
Acute lymphoblastic leukemia in first complete remission	--	1/1	--	--	--	--	--	1/1
Acute lymphoblastic leukemia in second complete remission	1/1	--	--	--	--	1/1	--	2/2
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure	--	0/1	--	--	--	--	--	0/1
Acute myelogenous leukemia in first complete remission	--	0/1	--	--	0/2	0/1	1/2	1/6
Acute myelogenous leukemia in second complete remission	0/1	--	--	--	--	1/1	--	1/2
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure	--	--	1/2	--	1/1	0/2	1/4	3/9
Chronic lymphocytic leukemia	--	--	--	--	--	--	1/1	1/1
Chronic myelogenous leukemia in accelerated phase or second chronic phase	--	--	--	--	--	1/1	--	1/1
Hodgkin lymphoma	--	--	--	--	2/2	--	--	2/2
Multiple myeloma / Plasma cell disorder	--	--	--	--	1/1	--	--	1/1
Myelodysplastic disorders - Other MDS	--	--	--	--	--	0/1	--	0/1
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2))	0/1	--	1/1	--	--	--	--	1/2
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast	--	--	--	--	--	2/2	--	2/2
Myeloproliferative syndromes	--	--	--	--	--	1/1	0/1	1/2
Non-Hodgkin lymphoma	--	--	1/1	--	1/1	--	--	2/2
Solid tumors / Other malignancies	--	1/1	--	--	--	--	--	1/1
Total	1/3	2/4	3/4	--	5/7	6/10	3/8	20/36